Sam Chun Dang Pharm to acquire 61.27% stake in DHP Korea - MarketLine Financial Deals

Sam Chun Dang Pharm to acquire 61.27% stake in DHP Korea

Sam Chun Dang Pharm to acquire 61.27% stake in DHP Korea - MarketLine Financial Deals
Sam Chun Dang Pharm to acquire 61.27% stake in DHP Korea
Published Dec 26, 2012
2 pages — Published Dec 26, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Sam Chun Dang Pharm. Co., Ltd., a pharmaceutical company, is planning to acquire 2.14 million shares, representing a 61.27% stake of DHP Korea Co., Ltd.

  
Source:
Document ID
MA133533_130103
Country
Ticker
000250=KR
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Sam Chun Dang Pharm to acquire 61.27% stake in DHP Korea" Dec 26, 2012. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Sam-Chun-Dang-Pharm-to-acquire-61-27-stake-in-DHP-Korea-2052-91758>
  
APA:
MarketLine Financial Deals. (2012). Sam Chun Dang Pharm to acquire 61.27% stake in DHP Korea Dec 26, 2012. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Sam-Chun-Dang-Pharm-to-acquire-61-27-stake-in-DHP-Korea-2052-91758>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.